A recent study has identified Aprepitant, one of the NK-1R antagonists, as an efficient inhibitor of hepatoblastoma tumor growth by decreasing β-catenin levels and downregulating the Wnt target genes AXIN2 and LGR5 (88). This evidence concerns the gene AXIN2 and hepatoblastoma.